Login / Signup

TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases.

Fortunato MorabitoGiovanni Del PoetaFrancesca Romana MauroGianluigi RedaPaolo SportolettiLuca LaurentiMarta CosciaYair HerishanuSabrina BossioMarzia VarettoniRoberta MurruAnnalisa ChiarenzaAndrea VisentinAdalgisa CondoluciRiccardo MoiaDaniela PietrasantaGiacomo LosetoUgo ConsoliIlaria ScortechiniAnna Grazia RecchiaFrancesca Romana MauroAntonella ZucchettoHamdi Al-JanazrehEnrica Antonia MartinoErnesto VignaGiovanni TripepiGraziella D'ArrigoSara GalimbertiAngela RagoIlaria AngelettiAnnalisa BiagiIlaria Del GiudiceRiccardo BombenAntonino NeriGilberto FronzaGiovanna CutronaOzren JaksicJacopo OlivieriDavide RossiFrancesco Di RaimondoAntonio CuneoGianluca GaidanoAaron PolliackLivio TrentinRobin FoàManlio FerrariniValter GatteiMassimo Gentile
Published in: American journal of hematology (2021)
Keyphrases
  • chronic lymphocytic leukemia
  • risk factors
  • cross sectional
  • double blind
  • clinical trial